White Paper

Launch Your Cell Or Gene Therapy With These Commercial Manufacturing Scaling Strategies

Source: ElevateBio
GettyImages-2187764040-cell-culture-testing-manufacturing-in-lab

With the potential to treat devastating indications such as cancer, genetic disorders, and rare diseases, cell and gene therapies (CGTs) offer life-saving possibilities for patients. However, the manufacture of CGTs is complex and highly specialized; to deliver these drugs to patients at commercial scale, drug sponsors must design processes and protocols that maintain quality and efficacy while ensuring scalability. ElevateBio’s BaseCamp? was designed with this goal in mind.

The facility was built to accommodate phase-appropriate manufacturing and development of advanced therapies, including autologous, allogeneic, viral vector, and mRNA products, while hurdling the obstacles of CGT scale-up. To scale production to meet commercial demand, ElevateBio offers demand modeling to support proactive planning, a range of suite sizes and accommodations, and a digital infrastructure that supports rapid scale-up and seamless tech transfer. Download the full article to explore the possibilities of a space centered around commercial scalability.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene